Public announcement · German Federal Institute for Risk Assessment · 2025-10-30
A 2025 assessment from Germany’s BfR considered supplements designed to deliver a large amount at one time.
Germany’s Federal Institute for Risk Assessment examined supplements intended to deliver large single doses of vitamin D days or weeks apart. Its 2025 assessment cited an annual-dose trial in older women that recorded more falls and fractures, and a monthly-dose trial in older adults that recorded more falls in the higher-dose groups.
The institute also examined products that combined vitamins D and K2. It found gaps in the evidence for particular amounts and schedules on the market. Its assessment addressed supplements and set medically prescribed treatment outside its scope.
The institute compared the amounts in the products it assessed with amounts used in research. It noted that the supplements supplied smaller single doses than those in the trials that reported more falls or fractures. It also considered the risk of taking a product again before the stated interval had passed.
